J. Vinholes

Hospital de Sant Pau — Spain

Medicine · Health Sciences

21h-index5.9kcitations50works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(22), Cancer Treatment and Pharmacology(14), Breast Cancer Treatment Studies(13), Cancer Diagnosis and Treatment(12), HER2/EGFR in Cancer Research(10)

Publications50 total

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of Clinical Oncology·2019· 143 citedOpen Access
Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
Cancer Research·2019· 10 cited
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
European Journal of Cancer·2017· 19 citedOpen Access
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
The Lancet·2015· 1.2k cited
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
Investigational New Drugs·2013· 41 citedOpen Access
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Journal of Clinical Oncology·2013· 389 cited
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
The Lancet Oncology·2012· 221 cited
A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
Journal of Clinical Oncology·2012· 10 cited
5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)
European Journal of Cancer·2011· 54 cited
First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study
Annals of Oncology·2011· 51 citedOpen Access
Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer
Cancer Research·2010· 3 cited
Real-life data on the effectiveness of fulvestrant (F) in postmenopausal breast cancer (BC): A multicenter study from Brazil.
Journal of Clinical Oncology·2010
Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.
Cancer Research·2009· 6 cited
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Annals of Oncology·2009· 47 citedOpen Access
Breast cancer in women over 80's: a case report of 14 patients
European Journal of Cancer Supplements·2008
2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
European Journal of Cancer Supplements·2007· 5 cited
Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen
Gastric Cancer·2006· 5 citedOpen Access
Adjuvant Docetaxel for Node-Positive Breast Cancer
New England Journal of Medicine·2005· 950 citedOpen Access
Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer
Journal of Clinical Oncology·2004· 10 cited
Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer
Journal of Clinical Oncology·2004· 8 cited
page 1 of 3Next →

Frequent Co-authors

Robert E. Coleman(14), O.P. Purohit(10), Richard Eastell(6), Louis Lacombe(5), Miguel Martín(5), RE Coleman(5), Álvaro Rodríguez-Lescure(4), José Bines(4), Donald M. Gleason(4), Robin Murray(4), Simon Tchekmedyian(3), Gilberto Schwartsmann(3), Carlos H. Barrios(3), Tadeusz Pieńkowski(3), John R. Mackey(3), Eva Tomiak(3), É Juhos(3), Tommy� Fornander(3), John D. Hainsworth(3), Manuel Modiano(3)